
- June 2014
- Volume 15
- Issue 6
Recognizing the Giants
We are pleased to present the second class of leading oncology specialists whom an esteemed advisory board has chosen to honor with our 2nd Annual Giants of Cancer Careâ„¢ awards.
OncLive Chairman,
Mike Hennessy
This month marks a happy anniversary for OncologyLive and the entire Intellisphere® Oncology Specialty Group.
We are pleased to present the second class of leading oncology specialists whom an esteemed advisory board has chosen to honor with our 2nd Annual Giants of Cancer Care™ awards.
Indeed, we feel a sense of privilege to have this opportunity to recognize individuals whose talent and dedication has improved the lives of countless patients.
As oncology information service providers, we are continually impressed by the level of commitment that the entire oncology community brings to the challenging spectrum of care that patients diagnosed with this devastating disease require.
Like so many Americans, many of us have been personally affected by cancer through the experiences of a friend or loved one. We know about that dedication firsthand.
We have made it a corporate priority to salute those who have contributed so richly to the remarkable progress against cancer currently under way.
In 2013, the inaugural Giants awards celebrated the achievements of 12 researchers whose discoveries have propelled the field forward and established the building blocks for future advances.
This year, we expanded the field to include 16 winners, 11 of whom were recognized for their innovations regarding particular tumor types and five who were honored in specialty categories.
In June, the advisory board that chose these winners will announce a Pioneer honoree—an individual who has already accomplished his or her most notable contributions.
We invite you to join in the conversation about the impact that advances promulgated by these Giants have had on your ability to help patients. As always, thank you for reading.
Articles in this issue
almost 12 years ago
CLL Researcher Excited About Outlook for CDK Inhibitorsalmost 12 years ago
Novel Therapies, Strategies in Development for NSCLCalmost 12 years ago
Lost in Translation: Objectivity Can Be Elusive in Clinical Trial Reportingalmost 12 years ago
Communication Challenges Loom as Germline Versus Somatic Cancer Data Evolvealmost 12 years ago
50th Anniversary Report: Even More Known About Smoking, Cancer Connectionsalmost 12 years ago
New Methods of Boosting Response to Bladder Cancer Immunotherapy Exploredalmost 12 years ago
Nab-Paclitaxel Compares Favorably in Pancreatic Cost-Effectiveness Study






























































